• Messoud Ashina, Peter J Goadsby, Uwe Reuter, Stephen Silberstein, David Dodick, Gregory A Rippon, Jan Klatt, Fei Xue, Victoria Chia, Feng Zhang, Sunfa Cheng, and Daniel D Mikol.
• Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
• Cephalalgia. 2019 Oct 1; 39 (11): 1455-1464.

BackgroundPreviously published three-month placebo-controlled and one-year open-label clinical trial data have provided information on the efficacy and safety of erenumab.MethodsInterim analysis was undertaken from an ongoing five-year open-label treatment phase after all patients completed three years in the open-label treatment phase or discontinued the study. Adult patients with episodic migraine enrolled in the open-label treatment phase initially received 70 mg erenumab monthly. A protocol amendment increased the dosage to 140 mg monthly to assess long-term safety of the higher dose. Safety and tolerability were assessed by monitoring adverse events, electrocardiograms, laboratory assessments, and vital signs.ResultsOf 383 patients enrolled in the open-label treatment phase, at data cutoff 235 (61.3%) remained in the study, all received 140 mg for ≥1 year. Median (Q1, Q3) exposure (70 or 140 mg) for all patients enrolled was 3.2 (1.3, 3.4) years. The most frequent adverse events (≥4.0/100 patient-years) were reported as viral upper respiratory tract infection, sinusitis, influenza, and back pain. Exposure-adjusted serious adverse event rates were 4.2/100 patient-years. There was no increase in cardiovascular events over time.ConclusionsIn this long-term study of a CGRP-receptor antibody, erenumab was found to be safe and well-tolerated with a spectrum and rate of adverse events consistent with shorter-term placebo-controlled studies.Trial RegistrationClinicalTrials.gov NCT01952574.

15 keywords...

hide…